A phase I study of liposomal doxorubicin (Doxil) with topotecan

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 23, Issue 3, 2000, Pages 297-300

  Ryan, Christopher W ^a   Fleming, Gini F ^a   Janisch, Linda ^a   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Clinical trials; Doxorubicin; Ovarian neoplasms; Phase I; Topotecan

Indexed keywords

DOXORUBICIN; HYCAMPTIN; LIPOSOME; TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; THROMBOCYTOPENIA;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; OVARIAN NEOPLASMS; THROMBOCYTOPENIA; TOPOTECAN;

EID: 0034445444     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200006000-00019     Document Type: Article

References (18)

1. Chemotherapy of ovarian cancer
2. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo
3. Increased microvascular permeability contributes to preferential accumulation of STEALTH liposomes in tumor tissue
4. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
5. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
6. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
7. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study
8. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma
9. Synergistic cytotoxicity with combined inhibition of topoisomerase topo I and II
10. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients
11. Measurement of tumor topoisomerase I and II levels during the sequential administration of Hycamptin and etoposide
12. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: A randomized, double-blind clinical trial using a canine model
13. Phase I study of topotecan in patients with impaired renal function
14. Clinical guidelines for managing topotecan-related hematologic toxicity
15. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies
16. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study
17. A phase II study of oral topotecan as a single agent, second-line therapy, administered for five days in patients with advanced ovarian cancer
18. Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid turnouts